Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model - Archive ouverte HAL Access content directly
Journal Articles Heliyon Year : 2023

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

Franck Touret

Abstract

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challenge model.
Fichier principal
Vignette du fichier
1-s2.0-S2405844023038719-main.pdf (356.64 Ko) Télécharger le fichier
Origin Publication funded by an institution
Licence

Dates and versions

hal-04584291 , version 1 (18-04-2023)
hal-04584291 , version 2 (24-05-2024)

Licence

Identifiers

Cite

Cécile Hérate, Romain Marlin, Franck Touret, Nathalie Dereuddre-Bosquet, Flora Donati, et al.. Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model. Heliyon, 2023, 9 (6), pp.e16664. ⟨10.1016/j.heliyon.2023.e16664⟩. ⟨hal-04584291v2⟩
123 View
41 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More